AstraZeneca explores $400bn megadeal with US rival

UK drugmaker Astrazeneca is exploring a $400bn merger with US rival Bristol Myers Squibb, in a deal that would create one of the world’s largest pharmaceutical groups. The FTSE 100 giant has held talks with the American group in recent months, according to reports in the Financial Times. Negotiations could lead to a deal in the near future, but also risk being delayed or falling apart, people familiar with the matter told the newspaper. Any potential transaction would likely consist of a combination of both cash and shares, the people said. Astrazeneca has a market valuation of £196bn. New York listed Bristol Myers Squibb has a market value of roughly $133bn (£98.6bn). Astrazeneca’s share price declined 7.1 per cent in early trading to 11,726p per share. The group’s share price has risen 13.4 per cent in the twelve months, while Bristol Myers Squibb has increased 43.8 per cent. The deal has also triggered questions over Astrazeneca’s ties to the UK, as its chief executive Sir Pascal Soriot pushes ahead with a pivot towards North America, previously describing the company as a “very American company”. Last September, the drugmaker upgraded its listing on the New York stock exchange, allowing US investors to buy it directly. The elevation put its US listing on par with that of London, which was viewed as a blow to the struggling UK market. The group went on to strike a $50bn deal with Donald Trump’s administration to invest in US manufacturing and transatlantic research facilities. The company currently operates 23 sites across 11 states, ranging from research and development to manufacturing. For investors in the UK, the potential combination signals a deepening shift in how the global healthcare industry operates. While the headquarters might remain in Cambridge, the economic logic of such a merger often favors the market with the deepest pockets, creating a structure where decisions are made in New York and profits are booked in the US. Britain’s biggest drugmaker has insisted that it intends to remain based in Cambridge and retain its London listing. It promised to plough £300m into its UK operations in April, just months after cancelling investments into a new lab in Cambridge and a site in Macclesfield. Astrazeneca faces a similar scrutiny regarding cash flow management as the sport grapples with a refund crisis over cancelled races. The potential tie-up comes as the healthcare sector sees consolidation, mirroring broader financial market trends. Critics argue the shift of profit centers to the US undermines the original national base. Some analysts believe the merger will proceed despite these concerns. Others predict a delay. Ultimately, the focus remains on the financials. The numbers suggest a powerful entity is emerging. Bristol Myers Squibb’s valuation adds significant weight to the talks. Astrazeneca brings its own set of assets to the table. The combined entity would be massive. This is a landmark potential agreement. The UK government will likely watch closely. Washington will also be interested in the outcome. The merger represents a major strategic move. It changes the competitive setting. Industry rivals are taking notice. The market reaction has been volatile. Shareholders are waiting for clarity. Rumors continue to circulate. The clock is ticking for a final decision. The outcome will be closely watched by the industry.